全球成癮症治療藥市場：2008年至2023年

全球成癮症治療藥市場：2008年至2023年 是由出版商Visiongain在2008年11月所出版的。 這份英文市場調查報告書包含138 pages 價格從美金2331起跳。

簡介

目錄

Abstract

The global addiction market is significantly undervalued. The world' s population has a large unmet need for addiction therapy drugs. Are you ready for the opportunities this presents? The brand new report, The Global Anti-Addiction Market, 2008-2023, provides an in-depth analysis of the current state of the market for addiction therapy drugs, from the present looking forward. It covers the major therapy areas of smoking cessation, obesity, drug addiction and alcohol dependency. In addition, this study forecasts how your market will grow and develop, both quantitatively and qualitatively, during the period 2008-2023.

The Global Anti-Addiction Market, 2008-2023, uses a variety of primary and secondary research methods, including:

• Exclusive visiongain interviews with key opinion leaders in the addiction industry
• Examination of a wealth of secondary sources, including company reports, filings, analyst presentations and press releases
• Use of in-house and commercial sales databases.

Addiction rates are increasing, yet there is a relative lack of widely-efficacious drugs. Also, relatively few patients are treated and patient compliance is low for those who are treated at present. Nevertheless, the growth potential market of this market is significant, both in developed and developing countries. In addition, awareness of the human and healthcare costs associated with addiction is increasing amongst patients, healthcare practitioners and legislators. There is a sense of urgency to combat tobacco addiction, alcoholism and obesity in particular. Consequently, there are marked opportunities for companies marketing and developing anti-addiction drugs. But by how much will the market grow and which therapy areas will be the fastest growing? This report answers those questions and more besides.

Visiongain has applied detailed financial forecasting and analysis of market/industry drivers and restraints, including SWOT analysis. The resulting comprehensive market-based report reveals how leading addiction brands, therapy areas and markets will fare during the period 2008 to 2023. Key features of the addiction drugs of the future and the hurdles they will have to overcome for commercial success are discussed.

• Expert opinion from representatives in the anti-addiction drug industry
• Sales forecasts for the global addiction market and for individual obesity, smoking cessation, drug addiction and alcohol addiction markets, including leading brands, manufacturers and country markets
• Examination of strengths, weakness, opportunities and threats (SWOT) facing major stakeholders in the anti-addiction drugs market
• In-depth analysis of the anti-addiction pipeline
• Geographical breakdown of the anti-addiction drugs market
• Analysis of the addiction markets in the US, France and the UK.

• To receive a comprehensive analysis of the prospects for anti-addiction drugs, including key metrics and predicted revenues, by type of addiction and brand
• To receive forecasts of addiction drug sales, from 2008-2023, in leading country markets, including China and Mexico
• To read the views of experts in the addiction industry, regarding current and future trends, opportunities and sales drivers; the report includes full transcripts of interviews
• The report is packed with graphs, charts, figure and tables of analysis and sales forecasts
• To determine the forces that influence the market for anti-addiction drugs: drivers, restraints, opportunities and competitive factors
• To find out where the addiction market is heading - both technologically and commercially from 2008 onwards.

The information contained in this report is not available in any other source and is essential reading for you and your colleagues. By ordering and reading this report you can gain market advantage on your competitors today. When aligned with your in-house findings we are confident you will continue to succeed over the next 15 years.

Table of Contents

1. Executive Summary

2. Introduction: Worldwide Prevalence and Treatment of Addiction

• 2.1 The Physiology and Psychology of Addiction
  • 2.1.1 Definition of Addiction
  • 2.1.2 Addiction is Caused by Physical Dependence
  • 2.1.3 Psychological Dependence
• 2.2 Prevalence of Addiction
• 2.3 Addiction Therapy
  • 2.3.1 Behavioural Therapy
  • 2.3.2 Addiction Treatment with Drugs
  • 2.3.3 Off-Label Drug Prescribing for Addiction Therapy
• 2.4 Smoking Cessation Products
  • 2.4.1 Nicotine Replacement Therapy (NRT)
  • 2.4.2 Nicotine Replacement Therapy Products (Johnson & Johnson)
  • 2.4.3 Nicotine Replacement Therapy Products (GSK)
  • 2.4.4 Nicotine Replacement Therapy Products (Novartis)
  • 2.4.5 Chantix/Champix (Pfizer)
  • 2.4.6 Zyban (GSK/Biovail)
• 2.5 Obesity Drugs
  • 2.5.1 Xenical (Roche)
  • 2.5.2 Reductil/Meridia (Abbott Laboratories)
  • 2.5.3 Alli (GSK)
  • 2.5.4 Acomplia (Sanofi-Aventis)
  • 2.5.5 Other Obesity Drugs
• 2.6 Drugs Used In Opioid Dependence
  • 2.6.1 Suboxone/Subutex (Reckitt Benckiser/ Schering-Plough)
  • 2.6.2 Methadone
  • 2.6.3 Naltrexone
  • 2.6.4 Other Drugs Used in Opioid Addiction Treatment
• 2.7 Alcohol Dependency Drugs
  • 2.7.1 Campral/Aotal (Merck KGaA/Forest)
  • 2.7.2 Antabuse (Barr)
  • 2.7.3 Naltrexone
  • 2.7.4 Vivitrol (Alkermes/Cephalon/Johnson & Johnson)
  • 2.7.5 Revia (Barr/Bristol-Myers Squibb)

3. The Global Addiction Market

• 3.1 The Addiction Market in 2007
  • 3.1.1 Leading Addiction Therapy Areas, 2007
  • 3.1.2 Leading Addiction Brands, 2007
  • 3.1.3 Leading Manufacturers of Addiction Drugs, 2007
• 3.2 Global Addiction Market Forecasts, 2008-2023
  • 3.2.1 Addiction Market Forecast, 2008-2023
  • 3.2.2 Addiction Therapy Area Sales Forecast, 2008-2023

4. The Global Smoking Cessation Market

• 4.1 The Smoking Cessation Market in 2007
  • 4.1.1 Leading Smoking Cessation Product Types, 2007
  • 4.1.2 Leading Manufacturers of Smoking Cessation Products, 2007
• 4.2 Smoking Cessation Market Forecasts, 2008-2023
  • 4.2.1 Global Smoking Cessation Market Forecast, 2008-2023
  • 4.2.2 Smoking Cessation Product Type Sales Forecast, 2008-2023
  • 4.2.3 Chantix/Champix Sales Forecast, 2008-2023

5. The Global Obesity Market

• 5.1 The Obesity Market in 2007
  • 5.1.1 Leading Obesity Brands, 2007
  • 5.1.2 Leading Manufacturers of Obesity Drugs, 2007
• 5.2 Obesity Market Forecasts, 2008-2023
  • 5.2.1 Global Obesity Market Forecast, 2008-2023
  • 5.2.2 Xenical Sales Forecast, 2008-2023
  • 5.2.3 Reductil/Meridia Sales Forecast 2008-2023
  • 5.2.4 Alli Sales Forecast, 2008-2023
  • 5.2.5 Acomplia Sales Forecast, 2008-2023

6. The Global Drug Addiction Market

• 6.1 The Drug Addiction Market in 2007
  • 6.1.1 Leading Drug Addiction Product Types, 2007
  • 6.1.2 Leading Manufacturers of Drug Addiction Products, 2007
• 6.2 Drug Addiction Market Forecasts, 2008-2023
  • 6.2.1 Global Drug Addiction Market Forecast, 2008-2023
  • 6.2.2 Drug Addiction Product Type Sales Forecast, 2008-2023
  • 6.2.3 Suboxone/Subutex Sales Forecast, 2008-2023

7. The Global Alcohol Dependency Market

• 7.1 The Alcohol Dependency Market in 2007
  • 7.1.1 Leading Alcohol Dependency Drug Types, 2007
  • 7.1.2 Leading Manufacturers of Alcohol Dependency Drugs, 2007
• 7.2 Alcohol Dependency Market Forecasts, 2008-2023
  • 7.2.1 Global Alcohol Dependency Market Forecast, 2008-2023
  • 7.2.2 Alcohol Dependency Drug Type Sales Forecast, 2008-2023
  • 7.2.3 Campral/Aotal Forecast, 2008-2023
  • 7.2.4 Vivitrol Sales Forecast, 2008-2023

8. Leading Addiction Country Markets

• 8.1 Top Twelve Addiction Country Markets, 2007
• 8.2 Addiction Market Country Forecasts, 2008-2023
• 8.3 The US Addiction Market
  • 8.3.1 Prevalence of Addiction in the US
  • 8.3.2 Smoking Cessation Dominated the US Addiction Market in 2007
  • 8.3.3 Forecast for the US Addiction Market, 2008-2023
• 8.4 The UK Addiction Market
  • 8.4.1 Prevalence of Addiction in the UK
  • 8.4.2 There is Greater Reimbursement of Addiction Drugs in the UK Market
  • 8.4.3 Forecast for the UK Addiction Market, 2008-2023
• 8.5 The French Addiction Market
  • 8.5.1 Prevalence of Addiction in France
  • 8.5.2 France has High Revenues in the Drug and Alcohol Addiction Markets
  • 8.5.3 Forecast for the French Addiction Market, 2008-2023

9. SWOT Analysis of the Addiction Market

• 9.1 Analysis of the Market
• 9.2 Strengths of the Addiction Industry
  • 9.2.1 Development of Addiction Vaccines and Novel Drug Formulations
  • 9.2.2 Expansion into New Therapeutic Areas
• 9.3 Weaknesses of the Addiction Therapy Industry
  • 9.3.1 Currently Marketed Addiction Therapies Lack Efficacy
  • 9.3.2 Poor Patient Compliance
• 9.4 Opportunities in the Addiction Market
  • 9.4.1 Addiction is Prevalent Worldwide and Increasing
  • 9.4.2 Prevalence of Tobacco Use Worldwide and in Major Country Markets
  • 9.4.3 Prevalence of Obesity Worldwide and in Major Country Markets
  • 9.4.4 Prevalence of Drug Use Worldwide and in Major Country Markets
  • 9.4.5 Alcohol Consumption and Dependence Worldwide and in Major Country Markets
  • 9.4.6 There is Considerable Under-Treatment of Patients
  • 9.4.7 The Cost of Addiction is High
  • 9.4.8 Awareness of the Costs of Addiction is Increasing
  • 9.4.9 Smoking Legislation is Spreading
• 9.5 Threats to the Addiction Market
  • 9.5.1 Reimbursement is the Key to Success in the Addiction Market
  • 9.5.2 Concern over Side-Effects of Addiction Drugs
  • 9.5.3 Behavioural Therapy is Often Preferred to Treatment with Drugs
  • 9.5.4 Social Stigma and Lack of Education and Resources

10. The Addiction Therapy Pipeline

• 10.1 Some Areas of the Addiction Pipeline are Stronger than Others
• 10.2 The Smoking Cessation Product Pipeline
  • 10.2.1 Addiction Vaccines Will Target Nicotine Dependence
  • 10.2.2 Surinabant (Sanofi-Aventis)
  • 10.2.3 EVT 302 (Evotec)
  • 10.2.4 NicVAX (Nabi Biopharmaceuticals)
  • 10.2.5 NIC002 (Cytos Biotechnology/Novartis)
  • 10.2.6 TA-NIC (Celtic Pharma)
  • 10.2.7 Niccine (Independent Pharmaceutica)
  • 10.3 The Obesity Drug Pipeline
    • 10.3.1 The Obesity Pipeline has had a High Failure Rate
    • 10.3.2 Contrave (Orexigen)
    • 10.3.3 CP-945598/Otenabant (Pfizer)
    • 10.3.4 Lorcaserin (Arena)
    • 10.3.5 Qnexa (Vivant)
    • 10.3.6 ATL-962/Cetilistat (Alizyme/Takeda)
    • 10.3.7 Pramlintide/Metreleptin (Amylin)
    • 10.3.8 Histalean (OBEcure)
    • 10.3.9 Empatic (Orexigen)
    • 10.3.10 Liraglutide (Novo Nordisk)
• 10.4 The Drug Addiction Therapy Pipeline
  • 10.4.1 Cocaine Treatment is the Most Promising Drug Addiction Pipeline Area
  • 10.4.2 Vivitrol (Alkermes)
  • 10.4.3 Probuphine (Titan)
  • 10.4.4 TA-CD (Celtic Pharma)
  • 10.4.5 SYN-117 (Synosia Therapeutics/Roche)
  • 10.4.6 Lobeline (Yaupon Therapeutics)
  • 10.4.7 Naltrexone Implant (Indevus)
  • 10.4.8 Tetrodin (WEX Pharmaceuticals)
  • 10.4.9 XY2401 (Xytis/National Institute on Drug Abuse/Rottapharm)
• 10.5 The Alcohol Dependency Therapy Pipeline
  • 10.5.1 The Alcohol Dependency Pipeline Has Plenty of Room for Novel Products
  • 10.5.2 Nalmefene (Biotie Therapies /Lundbeck/Somaxon): A New Drug for Dependency Disorders
  • 10.5.3 Naltrexone Depot (Elbion NV)
  • 10.5.4 ALKS 29 (Alkermes)
• 10.6 The Pipeline for Other Addiction Therapies

11. Expert Opinion from Key Opinion-Leaders in the Addiction Industry

• 11.1 Dr Raafat Fahim, President and Chief Executive Officer, Nabi Biopharmaceuticals
  • 11.1.1 Vaccines in the Pipeline for Nicotine Addiction
  • 11.1.2 NicVAX
  • 11.1.3 Other Nicotine Vaccines
• 11.2 Industry Representative from the Addiction Therapy Sector
  • 11.2.1 Type of Addictions with Greatest Market Growth Potential
  • 11.2.2 Key Unmet Needs For Alcohol Dependent Patients
  • 11.2.3 Key Advantages of Nalmefene
  • 11.2.4 The Future of the Alcohol Dependency Market

12. Conclusions

• 12.1 The Addiction Market in 2007
• 12.2 Opportunity for Growth in the Addiction Market
• 12.3 Visiongain' s Forecast for the Addiction Market, 2008-2023

• Table 2.1 Global Prevalence of Addiction and Drug Use
• Table 2.2 Key Drugs Prescribed Off-Label for Addiction Therapy
• Table 2.3 Major Johnson & Johnson Nicotine Replacement Therapy Brands
• Table 2.4 Major GSK Nicotine Replacement Therapy Brands
• Table 2.5 Major Novartis Nicotine Replacement Therapy Brands
• Table 3.1 Leading Addiction Therapy Areas, 2007
• Table 3.2 Leading Addiction Brands, 2007
• Table 3.3 Leading Manufacturers of Addiction Drugs, 2007
• Table 3.4 Global Addiction Market Forecast, 2008-2013
• Table 3.5 Global Addiction Market Forecast, 2014-2023
• Table 3.6 Addiction Therapy Area Sales Forecast, 2008-2013
• Table 3.7 Addiction Therapy Area Sales Forecast, 2014-2023
• Table 4.1 Leading Smoking Cessation Product Types, 2007
• Table 4.2 Leading Manufacturers of Smoking Cessation Products, 2007
• Table 4.3 Global Smoking Cessation Market Forecast, 2008-2013
• Table 4.4 Global Smoking Cessation Market Forecast, 2014-2023
• Table 4.5 Smoking Cessation Product Type Sales Forecast, 2008-2013
• Table 4.6 Smoking Cessation Product Type Sales Forecast, 2014-2023
• Table 5.1 Leading Obesity Brands, 2007
• Table 5.2 Leading Manufacturers of Obesity Drugs, 2007
• Table 5.3 Global Obesity Market Forecast, 2008-2013
• Table 5.4 Global Obesity Market Forecast, 2014-2023
• Table 5.5 Obesity Brands Sales Forecasts, 2008-2013
• Table 5.6 Obesity Brands Sales Forecasts, 2014-2023
• Table 6.1 Leading Drug Addiction Product Types, 2007
• Table 6.2 Leading Manufacturers of Drug Addiction Products, 2007
• Table 6.3 Global Drug Addiction Market Forecast, 2008-2013
• Table 6.4 Global Drug Addiction Market Forecast, 2014-2023
• Table 6.5 Drug Addiction Product Type Sales Forecast, 2008-2013
• Table 6.6 Drug Addiction Product Type Sales Forecast, 2014-2023
• Table 6.7 Suboxone/Subutex Sales Forecast, 2008-2013
• Table 6.8 Suboxone/Subutex Sales Forecast, 2014-2023
• Table 7.1 Leading Alcohol Dependency Drug Types, 2007
• Table 7.2 Leading Manufacturers of Alcohol Dependency Drugs, 2007
• Table 7.3 Global Alcohol Dependency Market Forecast, 2008-2013
• Table 7.4 Global Alcohol Dependency Market Forecast, 2014-2023
• Table 7.5 Alcohol Dependency Drug Type Sales Forecast, 2008-2013
• Table 7.6 Alcohol Dependency Drug Type Sales Forecast, 2014-2023
• Table 7.7 Campral/Aotal and Vivitrol Sales Forecast, 2008-2013
• Table 7.8 Campral/Aotal and Vivitrol Sales Forecast, 2014-2023
• Table 8.1 Top Twelve Addiction Country Markets, 2007
• Table 8.2 Addiction Market Country Forecasts, 2008-2013
• Table 8.3 Addiction Market Country Forecasts, 2014-2023
• Table 8.4 Prevalence of Addiction and Drug Use in the US
• Table 8.5 The US Addiction Market, 2007
• Table 8.6 Prevalence of Addiction and Drug Use in the UK
• Table 8.7 The UK Addiction Market, 2007
• Table 8.8 Prevalence of Addiction and Drug Use in France
• Table 8.9 The French Addiction Market, 2007
• Table 9.1 SWOT Chart for Addiction Market
• Table 9.2 Prevalence of Tobacco Use Worldwide and in Major Country Markets
• Table 9.3 Prevalence of Obesity Worldwide and in Major Country Markets
• Table 9.4 Worldwide Drug Use, 2006/07
• Table 9.5 Prevalence of Opioid Drug Use Worldwide and in Major Country Markets
• Table 9.6 Prevalence of Cocaine Use Worldwide and in Major Country
• Table 9.7 Alcohol Consumption & Dependence Worldwide & in Major Country Markets
• Table 10.1 Key Smoking Cessation Pipeline Products
• Table 10.2 Key Obesity Pipeline Drugs
• Table 10.3 Key Drug Addiction Pipeline Therapies
• Table 10.4 Key Alcohol Dependency Pipeline Drugs

List of Figures

• Figure 3.1 Leading Addiction Therapy Areas, 2007
• Figure 3.2 Leading Addiction Brands, 2007
• Figure 3.3 Leading Manufacturers of Addiction Drugs, 2007
• Figure 3.4 Global Addiction Market Forecast, 2008-2023
• Figure 3.5 Addiction Therapy Area Sales Forecast, 2008-2023
• Figure 3.6 Addiction Therapy Area Sales Forecast and Market Share, 2008-2023
• Figure 3.7 Addiction Therapy Area Market Share, 2013
• Figure 3.8 Addiction Therapy Area Market Share, 2018
• Figure 3.9 Addiction Therapy Area Market Share, 2023
• Figure 4.1 Leading Smoking Cessation Product Types, 2007
• Figure 4.2 Leading Manufacturers of Smoking Cessation Products, 2007
• Figure 4.3 Global Smoking Cessation Market Forecast, 2008-2023
• Figure 4.4 Smoking Cessation Product Type Sales Forecast, 2008-2023
• Figure 4.5 Smoking Cessation Product Type Sales Forecast & Market Share, 2008-2023
• Figure 4.6 Chantix/Champix Sales Forecast, 2008-2023
• Figure 5.1 Leading Obesity Brands, 2007
• Figure 5.2 Leading Manufacturers of Obesity Drugs, 2007
• Figure 5.3 Global Obesity Market Forecast, 2008-2023
• Figure 5.4 Xenical Sales Forecast, 2008-2023
• Figure 5.5 Reductil/Meridia Sales Forecast, 2008-2023
• Figure 5.6 Alli Sales Forecast, 2008-2023
• Figure 5.7 Acomplia Sales Forecast, 2008-2023
• Figure 6.1 Leading Drug Addiction Product Types, 2007
• Figure 6.2 Leading Manufacturers of Drug Addiction Products, 2007
• Figure 6.3 Global Drug Addiction Market Forecast, 2008-2023
• Figure 6.4 Drug Addiction Product Type Sales Forecast, 2008-2023
• Figure 6.5 Drug Addiction Product Type Sales Forecast and Market Share, 2008-2023
• Figure 6.6 Suboxone/Subutex Sales Forecast, 2008-2023
• Figure 7.1 Leading Alcohol Dependency Drug Types, 2007
• Figure 7.2 Leading Manufacturers of Alcohol Dependency Drugs, 2007
• Figure 7.3 Global Alcohol Dependency Market Forecast, 2008-2023
• Figure 7.4 Alcohol Dependency Drug Type Sales Forecast, 2008-2023
• Figure 7.5 Alcohol Dependency Drug Type Sales Forecast and Market Share, 2008-2023
• Figure 7.6 Campral/Aotal Sales Forecast, 2008-2023
• Figure 7.7 Vivitrol Sales Forecast, 2008-2023
• Figure 8.1 Leading Addiction Country Markets, 2007
• Figure 8.2 Leading Addiction Country Markets, 2013
• Figure 8.3 Leading Addiction Country Markets, 2018
• Figure 8.4 Leading Addiction Country Markets, 2023
• Figure 8.5 The US Addiction Market, 2007
• Figure 8.6 US Addiction Market Sales Forecast, 2008-2023
• Figure 8.7 The UK Addiction Market, 2007
• Figure 8.8 UK Addiction Market Sales Forecast, 2008-2023
• Figure 8.9 The French Addiction Market, 2007
• Figure 8.10 French Addiction Market Sales Forecast, 2008-2023
• Figure 9.1 Top-Ten Countries for Numbers of Tobacco Users
• Figure 9.2 Prevalence of Obesity in Major Country Markets
• Figure 9.3 Prevalence of Opioid Drug Use in Major Country Markets
• Figure 9.4 Prevalence of Cocaine Use in Major Country Markets
• Figure 9.5 Alcohol Consumption and Dependence in Major Country Markets

Companies Listed

• Abbott Laboratories
• Actavis
• Alizyme
• Alkermes
• Amylin
• Arena
• AstraZeneca
• Barr
• Biotie Therapies (Finland)
• Biovail
• Bristol-Myers Squibb
• Celtic Pharma
• Cephalon
• CV Therapeutics
• Cytos Biotechnology
• Drake University (US)
• Eisai
• Elbion NV
• Eli Lilly
• European Medicines Agency (EMEA)
• European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
• Evotec
• Food and Drug Administration (FDA)
• Forest
• GSK
• Independent Pharmaceutica
• Indevus
• Johnson & Johnson
• Karolinska Institutet (Sweden)
• Lundbeck
• Medley (Brazil)
• Merck & Co.
• Merck KGaA
• Nabi Biopharmaceuticals
• National Health Service (NHS, UK)
• National Institute for Health and Clinical Excellence (NICE, UK)
• National Institute on Drug Abuse (NIDA, USA)
• National Institutes of Health (NIH, USA)
• Novartis
• Novo Nordisk
• OBEcure
• Orexigen
• Pfizer
• Reckitt Benckiser
• Roche
• Rottapharm (Italy)
• Sanofi-Aventis
• Schering-Plough
• Solvay
• Somaxon
• Synosia Therapeutics
• Takeda
• Titan
• Vivant
• WEX Pharmaceuticals
• World Health Organization (WHO)
• Xytis
• Yaupon Therapeutics

相關商品

精神病相關市場調查報告書

抗精神病藥物市場(∼2017年):金普薩(Zyprexa)·安立復(Abilify)·思樂康(Seroquel)·哲思(Geodon)專利到期，及學名藥開始販售將限制開發平台分子商業機會的可能性
Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules
價格 : US $ 3500
出版日期 : 2012年01月

阿茲海默症：新藥・市場・企業
Alzheimer disease - new drugs, markets and companies
價格 : US $ 3500
出版日期 : 2012年01月

憂鬱症:針對二線患者的新一代產品競爭
Product Profiles: Depression - Next generation vies for second-line patients
價格 : US $ 11400
出版日期 : 2011年11月

Visiongain發行的製藥相關市場調查報告書

抗菌藥物：全球市場展望 2012-2022

Antibacterial Drugs: World Market Prospects 2012-2022

價格 : US $ 2642

出版日期 : 2011年11月

多發性硬化症治療：全球藥劑市場 2012-2022

Multiple Sclerosis Treatment: World Drug Market 2012-2022

價格 : US $ 2642

出版日期 : 2011年11月

全球小分子癌症標靶治療市場：2011-2021

Small-Molecule Targeted Cancer Therapies: World Market 2011-2021

價格 : US $ 2642

出版日期 : 2011年11月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!